We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

WHO Warning: Rapid Tests Misdiagnose Many Cases of P. falciparum Malaria in Africa

By LabMedica International staff writers
Posted on 05 Oct 2021
Print article
Image: Blood smear from a P. falciparum culture. Several red blood cells have ring stages inside them. Close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)
Image: Blood smear from a P. falciparum culture. Several red blood cells have ring stages inside them. Close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)
A pair of mutations, which result in deletion of the Plasmodium falciparum histidine-rich protein 2 (HRP2), render the malaria parasite invisible to the most commonly used rapid diagnostic tests.

In Africa, most rapid diagnostic tests (RDTs) for falciparum malaria recognize histidine-rich protein 2 antigen. Plasmodium falciparum parasites lacking histidine-rich protein 2 (pfhrp2) and 3 (pfhrp3) genes escape detection by these RDTs.

HRP2 is a histidine- and alanine-rich, water-soluble protein, which is localized in several cell compartments including the parasite cytoplasm. The antigen is expressed only by P. falciparum trophozoites. A substantial amount of the HRP2 is secreted by the parasite into the host bloodstream, and the antigen can be detected in erythrocytes, serum, plasma, cerebrospinal fluid, and even urine as a secreted water-soluble protein.

Investigators at the University of North Carolina School of Medicine (Chapel Hill, USA) used several advanced genomic tools to determine the extent of HRP2 deletions expressed by P. falciparum in Africa. Specifically, they analyzed blood samples from a cohort of 12,572 participants enrolled in a prospective, cross-sectional survey along Ethiopia’s borders with Eritrea, Sudan, and South Sudan using RDTs, multiple PCR assays, an ultrasensitive bead-based immunoassay for antigen detection, whole-genome sequencing (WGS) and/or molecular inversion probe (MIP) deep sequencing.

Results indicated that histidine-rich protein 2-based RDTs would miss approximately 9.7% of P. falciparum malaria cases owing to deletion of the pfhrp2 gene.

“This is a serious problem for malaria control efforts and a reminder that pathogens are very capable of adapting to survive,” said senior author Dr. Jonathan B. Parr, assistant professor of infectious diseases at the University of North Carolina School of Medicine. “Surveillance across the Horn of Africa and alternative malaria diagnostic approaches in affected regions are urgently needed. Our work indicates that prhrp3 deletions have arisen independently multiple times over the course of years. “We also found signs that RDT-based testing and treatment are driving a recent rise in pfhrp2 deletion mutation prevalence, allowing parasites to escape detection.”

The World Health Organization (WHO) now recommends that all malaria endemic countries start and maintain surveillance for pfhrp2/3 deletions and respond appropriately when they are confirmed, in order to prevent unnecessary morbidity and deaths and to safeguard inroads that have been made towards malaria elimination, particularly in sub-Saharan Africa.

The malaria RDT paper was published in the September 27, 2021, online edition of the journal Nature Microbiology.

Related Links:
University of North Carolina School of Medicine

Gold Supplier
Automated Nucleic Acid Extraction Workstation
Glucose & Lactate Measuremen Device
Isothermal Microfluidic Chip Analyzer
CapitalBio RTisochip
Zika, Chikungunya and Dengue Rapid Test
DPP ZCD IgM/IgG System

Print article


Copyright © 2000-2022 Globetech Media. All rights reserved.